TORONTO, March 15, 2016 /CNW/ - Teva Canada Limited, a subsidiary of
Teva Pharmaceutical Industries Ltd., announced that Health Canada has
approved its application for the generic version of PrKivexa®. This agent is indicated in antiretroviral combination therapy
for the treatment of Human Immunodeficiency Virus (HIV) infection in
PrKivexa® had annual sales of approximately $68.4 million in Canada, based on IMS
Brogan sales data as of December 2015. PrTeva-Abacavir/Lamivudine is available immediately in pharmacies across Canada. Teva Canada is the
first generic supplier of this treatment in Canada.
"Effective treatment options that minimize the viral load of HIV have
significantly contributed to Canadians living longer with this virus,"
said Doug Sommerville, General Manager, Teva Canada Limited. "As the
first generic supplier of Abacavir/Lamivudine tablets, we are pleased
to support the HIV community with a lower-cost bioequivalent version of
this important antiretroviral agent today."
According to the Public Health Agency of Canada, an estimated 75,500
Canadians were living with HIV at the end of 2014.1 While the prevalence rate of HIV infection is 212 per 100,000 people
living in Canada, it is estimated that 16,020 people living with HIV
remain undiagnosed in 2014.2 Early diagnosis and treatment intervention with antiretroviral therapy
provides the best option for significantly improved life expectancy.
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable
healthcare solutions for 50 years, with nearly 200,0003 prescriptions filled with our products every day. Originally Novopharm
Limited, Teva Canada Limited specializes in the development, production
and marketing of high-quality generic prescription pharmaceuticals and
through our branded division, Teva Canada Innovation, focuses on a
diverse line of innovative products in a variety of therapeutic areas.
Teva Canada employs more than 1,300 individuals, markets more than 4004 products in Canada and is a subsidiary of Teva Pharmaceutical Industries
Ltd., the world's largest generic drug maker. For more information,
visit: www.tevacanada.com or www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world's largest generic medicines
producer, leveraging its portfolio of more than 1,000 molecules to
produce a wide range of generic products in nearly every therapeutic
area. In specialty medicines, Teva has a world-leading position in
innovative treatments for disorders of the central nervous system,
including pain, as well as a strong portfolio of respiratory products.
Teva integrates its generics and specialty capabilities in its global
research and development division to create new ways of addressing
unmet patient needs by combining drug development capabilities with
devices, services and technologies. Teva's net revenues in 2015
amounted to $19.7 billion. For more information, visit www.tevapharm.com.
1 Public Health Agency of Canada. Summary: Estimates of HIV Incidence, Prevalence and Proportion
Undiagnosed in Canada, 2014. http://www.catie.ca/sites/default/files/2014-HIV-Estimates-in-Canada-EN.pdf. Accessed February 2016
3 IMS Compuscript TRx MAT December 2015
4 IMS CD&H MAT December 2015
SOURCE Teva Canada Limited
Image with caption: "(Pr)Teva-Abacavir/Lamivudine is available as 600 mg/300 mg tablets in bottles of 30 tablets and blisters of 30 tablets. (CNW Group/Teva Canada Limited)". Image available at: http://photos.newswire.ca/images/download/20160315_C9921_PHOTO_EN_44655.jpg
For further information:
Teva Pharmaceutical Industries Ltd.
Sr. Vice President, Global Corporate Reputation